US › Healthcare

Ocugen Inc (OCGN)

US · Healthcare · Biotechnology

$0.78-4.18%

Last close · 2026-10-16

Latest quarter · ended 2026-06-30

Revenue

$1.5M

Revenue YoY

+8.4%

Net profit

$-24.9M

EPS

$-0.07

EPS estimate

$-0.05

Net margin

-1,671.8%

EPS came in at -0.07 against a street estimate of -0.05 — a miss of 40.0%.

Key statistics

Market cap

$324.0M

Forward P/E

13.1

P/B

75.94

Book value

$-0.05

EPS (TTM)

$-0.26

52-week high

$2.73

52-week low

$0.90

50-day MA

$1.20

200-day MA

$1.48

Beta

2.27

Analyst view

Analysts rate Ocugen Inc a strong buy (6 buy, 0 hold, 0 sell out of 6) with an average price target of $12.17.

Shareholding

Insiders

1.54%

Institutions

43.41%

Largest institutional holders

Fund	Stake
BlackRock Inc	7.96%
State Street Corp	6.33%
Vanguard Capital Management, LLC	4.24%
Millennium Management LLC	4.11%
Geode Capital Management, LLC	2.62%
RTW INVESTMENTS, LLC	1.97%
UBS Group AG	1.53%
Ikarian Capital, LLC	1.17%

See the full picture

Technicals, trade setups with a published hit rate, AI analysis and earnings-call summaries for Ocugen Inc — free to start.

Open in the app Google Play App Store

Other Healthcare companies

Eli Lilly and Company Johnson & Johnson AbbVie Inc UnitedHealth Group Incorporated Merck & Company Inc Novartis AG ADR AstraZeneca PLC Thermo Fisher Scientific Inc Amgen Inc Gilead Sciences Inc Abbott Laboratories Novo Nordisk A/S

Data updated 2026-10-19.